These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37641577)

  • 1. Characterizing the emergence of amyloid and tau burden in Down syndrome.
    Zammit MD; Betthauser TJ; McVea AK; Laymon CM; Tudorascu DL; Johnson SC; Hartley SL; Converse AK; Minhas DS; Zaman SH; Ances BM; Stone CK; Mathis CA; Cohen AD; Klunk WE; Handen BL; Christian BT;
    Alzheimers Dement; 2024 Jan; 20(1):388-398. PubMed ID: 37641577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
    Wisch JK; McKay NS; Boerwinkle AH; Kennedy J; Flores S; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant SE; Price JC; Laymon CM; Krinsky-McHale SJ; Lai F; Rosas HD; Hartley SL; Zaman S; Lott IT; Tudorascu D; Zammit M; Brickman AM; Lee JH; Bird TD; Cohen A; Chrem P; Daniels A; Chhatwal JP; Cruchaga C; Ibanez L; Jucker M; Karch CM; Day GS; Lee JH; Levin J; Llibre-Guerra J; Li Y; Lopera F; Roh JH; Ringman JM; Supnet-Bell C; van Dyck CH; Xiong C; Wang G; Morris JC; McDade E; Bateman RJ; Benzinger TLS; Gordon BA; Ances BM; ;
    Lancet Neurol; 2024 May; 23(5):500-510. PubMed ID: 38631766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
    Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
    Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.
    Hartley SL; Fleming V; Schworer EK; Peven J; Handen BL; Krinsky-McHale S; Hom C; Lee L; Tudorascu DL; Laymon C; Minhas D; Luo W; Cohen A; Zaman S; Ances BM; Mapstone M; Head E; Lai F; Rosas HD; Klunk W; Christian B;
    J Alzheimers Dis; 2023; 95(1):213-225. PubMed ID: 37482997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Ellison PA; Zaman SH; Ances BM; Johnson SC; Stone CK; Sabbagh MN; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage Clin; 2021; 31():102740. PubMed ID: 34182407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight Loss and Alzheimer's Disease in Down Syndrome.
    Fleming V; Helsel BC; Ptomey LT; Rosas HD; Handen B; Laymon C; Christian BT; Head E; Mapstone M; Lai F; Krinsky-McHale S; Zaman S; Ances BM; Lee JH; Hartley SL;
    J Alzheimers Dis; 2023; 91(3):1215-1227. PubMed ID: 36565120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity.
    Costoya-Sánchez A; Moscoso A; Silva-Rodríguez J; Pontecorvo MJ; Devous MD; Aguiar P; Schöll M; Grothe MJ;
    JAMA Neurol; 2023 Oct; 80(10):1051-1061. PubMed ID: 37578787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
    Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
    Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome.
    Rafii MS
    Dev Neurobiol; 2019 Jul; 79(7):711-715. PubMed ID: 30536948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.